# Porcine Collagen Type V (Sus scrofa domesticus)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/porcine-collagen-type-v
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 2 / 10
**Category:** Protein
**Also Known As:** Type V collagen, Collagen V, Col5, Porcine type 5 collagen, Pig collagen type V, Swine collagen type V, Type V fibrillar collagen, Collagen alpha chains type V

## Overview

Porcine collagen type V, derived from Sus scrofa domesticus, is a fibrillar collagen that regulates collagen fibril diameter and supports tissue architecture through interactions with types I and III collagen. Its bioactive peptides demonstrate ACE inhibitory and dipeptidyl peptidase IV (DPP-IV) inhibitory activity, suggesting [cardiovascular](/ingredients/condition/heart-health) and metabolic support potential.

## Health Benefits

• May support tissue regeneration in surgical applications - animal studies show successful neointima formation and endothelialization (preliminary evidence)
• Contains bioactive peptides with potential ACE inhibitory activity (79.50%) and dipeptidyl peptidase IV inhibition (74.91%) - in vitro evidence only
• Demonstrates antiproliferative effects on vascular smooth muscle cells - laboratory studies show inhibition of cell cycle progression
• Shows biocompatibility without foreign body reactions in tissue engineering applications - animal model evidence
• No proven benefits for cardiometabolic health or [cognitive performance](/ingredients/condition/cognitive) - one human RCT (PMID: 41288414) found no improvement

## Mechanism of Action

Porcine collagen type V acts as a fibril nucleator, co-assembling with collagen type I to regulate fibril diameter by incorporating into the fibril core and limiting lateral growth via steric hindrance from its retained N-terminal propeptide. Its hydrolyzed peptides inhibit angiotensin-converting enzyme (ACE), reducing the conversion of angiotensin I to angiotensin II, thereby supporting [blood pressure regulation](/ingredients/condition/heart-health). Additionally, DPP-IV inhibition by these peptides slows the degradation of incretin hormones GLP-1 and GIP, which may support postprandial [glucose metabolism](/ingredients/condition/weight-management).

## Clinical Summary

Current evidence for porcine collagen type V is predominantly preclinical. Animal studies using porcine-derived collagen scaffolds have demonstrated successful neointima formation and endothelialization, supporting its potential in vascular tissue engineering applications. In vitro assays of enzymatic hydrolysates report ACE inhibitory activity of 79.50% and DPP-IV inhibitory activity of 74.91%, though these figures have not been confirmed in human pharmacokinetic or clinical trials. No controlled human clinical trials have been published specifically for type V porcine collagen supplementation, making the current evidence base preliminary and insufficient to establish therapeutic dosing or efficacy claims.

## Nutritional Profile

Porcine Collagen Type V is a fibrillar collagen protein comprising approximately 95-100% protein by dry weight with negligible fat, carbohydrate, and fiber content. Amino acid composition is dominated by glycine (~330 residues per 1000 amino acids, ~33%), proline (~130/1000, ~13%), and hydroxyproline (~95/1000, ~9.5%), forming the characteristic Gly-X-Y repeating triplet structure. Contains alanine (~11%), glutamic acid (~8%), arginine (~5%), and lesser quantities of serine, leucine, valine, and threonine. Notably deficient in tryptophan (essentially 0%) and low in methionine, cysteine, and histidine, classifying it as an incomplete protein by essential amino acid standards. Hydroxylysine content is approximately 5-7 residues per 1000, serving as glycosylation attachment sites carrying O-linked galactose and glucosyl-galactose moieties. Mineral content reflects tissue source: trace calcium (~0.1-0.3%), phosphorus, and magnesium may be present depending on extraction purity. No significant vitamin content. Bioactive peptides released upon hydrolysis demonstrate documented ACE inhibitory activity (IC50 values in the micromolar range; overall inhibition ~79.50% in vitro) and DPP-IV inhibition (~74.91% in vitro), attributed to proline-rich sequences such as IPP and VPP analogues. Molecular weight of intact alpha chains: ~140-145 kDa per chain; triple helix assembly ~400 kDa. Bioavailability of intact collagen is low due to limited digestibility; hydrolyzed forms (collagen peptides, MW <5 kDa) show substantially improved gastrointestinal absorption estimated at 90%+ in hydrolyzed form versus <10% for native fibrillar structure.

## Dosage & Preparation

No specific clinically studied dosage ranges for porcine collagen Type V supplementation have been established in the available research. The one human trial used a four-week supplementation protocol, but specific doses were not detailed. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Porcine collagen type V is generally considered low-risk for most populations when consumed in food-grade or supplement-grade preparations, but individuals with pork allergies or sensitivities should avoid it due to potential cross-reactivity with Sus scrofa proteins. Individuals taking ACE inhibitor medications such as lisinopril or enalapril should exercise caution, as the ACE-inhibitory peptides may produce additive hypotensive effects. Similarly, concurrent use with DPP-IV inhibitor drugs (e.g., sitagliptin, saxagliptin) could theoretically potentiate effects on incretin hormones, warranting medical supervision. Safety data in pregnant or breastfeeding women is absent, and use in these populations should be discussed with a healthcare provider.

## Scientific Research

Human clinical trial data for porcine collagen Type V remains extremely limited. One randomized controlled trial (PMID: 41288414) examining porcine collagen hydrolysate supplementation in overweight adults found no improvement in cardiometabolic risk markers or [cognitive performance](/ingredients/condition/cognitive) after four weeks. Two ongoing trials (NCT06622759, NCT11749683) are investigating porcine collagen matrix for tissue regeneration in dental applications.

## Historical & Cultural Context

The research does not contain information regarding historical or traditional use of porcine collagen Type V in traditional medicine systems. Modern use appears limited to biomedical applications and recent supplement development.

## Synergistic Combinations

Type I collagen, Type III collagen, Vitamin C, Hyaluronic acid, Copper

## Frequently Asked Questions

### What is porcine collagen type V and how is it different from type I collagen?

Porcine collagen type V is a minor fibrillar collagen derived from pig (Sus scrofa domesticus) tissues that functions primarily as a fibril initiator and diameter regulator, rather than a bulk structural protein like type I collagen. While type I collagen provides tensile strength in skin, bone, and tendon, type V collagen co-polymerizes within those fibrils and controls their thickness by remaining partially exposed at the fibril surface, which limits lateral accretion of additional collagen molecules.

### Can porcine collagen type V help with blood pressure?

In vitro studies of enzymatically hydrolyzed porcine collagen type V peptides report ACE inhibitory activity of approximately 79.50%, meaning these peptides can block the enzyme responsible for converting angiotensin I to the vasoconstrictive angiotensin II. However, this effect has only been demonstrated in cell-based assays and has not been replicated in human clinical trials, so definitive blood pressure-lowering claims cannot currently be made for supplemental use.

### Does porcine collagen type V support blood sugar control?

Bioactive peptides derived from porcine collagen type V hydrolysates have shown DPP-IV inhibitory activity of 74.91% in vitro, which theoretically could slow the breakdown of GLP-1 and GIP — incretin hormones that stimulate insulin release after meals. This mechanism parallels that of pharmaceutical DPP-IV inhibitor drugs like sitagliptin, but the effect for collagen-derived peptides has only been shown in laboratory conditions and requires human clinical validation before any glucose management claims can be supported.

### Is porcine collagen type V used in tissue engineering or surgery?

Yes, porcine-derived collagen type V scaffolds have been investigated in animal studies for vascular tissue engineering applications, with results showing successful neointima formation and endothelialization — indicating the scaffold supports the ingrowth of new tissue and blood vessel lining cells. These findings are promising for surgical and regenerative medicine contexts, though translation to human clinical applications requires further controlled research and regulatory evaluation.

### Is porcine collagen type V safe for people with pork allergies?

Individuals with documented pork or pork-derived protein allergies should avoid porcine collagen type V, as it retains antigenic proteins from Sus scrofa domesticus that can trigger IgE-mediated allergic responses, including urticaria, gastrointestinal distress, or in severe cases anaphylaxis. People who avoid pork for religious reasons (e.g., halal or kosher dietary laws) should also note that this ingredient is explicitly porcine in origin, and marine or bovine collagen type V alternatives may be more appropriate.

### What does the research evidence say about porcine collagen type V's effectiveness?

Current evidence for porcine collagen type V is primarily limited to in vitro (laboratory) and animal studies, which show promise for ACE inhibitory activity and vascular smooth muscle cell effects. Human clinical trials are largely absent, meaning real-world efficacy in people remains unproven. The tissue engineering and surgical applications show preliminary success in animal models, but translation to clinical practice requires further human research. Consumers should be aware that marketed health claims often exceed the strength of available scientific evidence.

### Does porcine collagen type V interact with blood pressure or diabetes medications?

While in vitro studies suggest porcine collagen type V may have ACE inhibitory and dipeptidyl peptidase IV-inhibiting properties similar to certain medications, there is no clinical evidence of direct drug interactions. However, if the ingredient does have blood pressure-lowering or glucose-modulating effects in humans, combining it with antihypertensive or antidiabetic medications could theoretically increase efficacy or risk hypotension/hypoglycemia. Anyone taking medications for hypertension or diabetes should consult their healthcare provider before supplementing with porcine collagen type V. Current evidence is insufficient to make specific interaction predictions.

### Who should avoid porcine collagen type V supplements?

Beyond individuals with documented pork allergies, those with bleeding disorders or taking anticoagulant medications should exercise caution, as collagen is involved in clotting mechanisms. Pregnant and nursing women should avoid this supplement due to lack of safety data in these populations. Vegans and vegetarians will want to avoid porcine collagen as it is animal-derived from pig sources. Anyone with existing cardiovascular or metabolic conditions should consult a healthcare provider before use, given the supplement's claimed (but unproven) effects on blood pressure and glucose.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*